takeda pharmaceutical co ltd
(4502:Tokyo Stock Exchange)
William W. Chin M.D.
Member of Takeda Global Advisory Board,Takeda Pharmaceutical Company Limited
|Age||Total Calculated Compensation||This person is connected to 71 board members in 5 different organizations across 7 different industries.|
See Board Relationships
Dr. William W. Chin, M.D. serves as an Executive Dean at Research, Bertarelli Professor for Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). Dr. Chin served as Senior Vice President of Discovery & Clinical Research at Eli Lilly and Company. Dr. Chin served as the Vice President of Discovery Biology Research and Clinical Investigation of Eli Lilly and Company since July 2003. Dr. Chin served as Vice President of gene regulation, ...
12-10, Nihonbashi 2-chomePhone: 81 3 3278 2111
Osaka, -- 103-8668
Fax: 81 3 3278 2000
Board Members Memberships*
Harvard Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Vincent A. Forlenza||Chairman, Chief Executive Officer, President and Chairman of Executive Committee|
Becton, Dickinson and Company
|Miles D. White||Chairman of The Board, Chief Executive Officer and Chairman of Executive Committee|
|José E. Almeida||Chairman and Chief Executive Officer|
Baxter International Inc.
|Lars Rebien Sørensen||Chief Executive Officer, President and Chairman of Operations Committee|
Novo Nordisk A/S
|Stefan Oschmann||Chairman of Executive Board, Chief Executive Officer and Chairman of Corporate Responsibility Committee|
|€5.4M||Compensation as of Fiscal Year 2015.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.